Kurve Therapeutics, Innovative Medtech and Specialty-Drug Company Focused on Treating Neurodegenerative Diseases, Files Regulation A Offering

Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 shares. Kurve Therapeutics is ready for Phase III clinical trials in three separate disease states and is positioned to make a critical impact on the neurodegenerative disease treatment market.

Kurve Therapeutics has developed a cutting-edge approach to treating central nervous system (CNS) disorders. These debilitating disorders afflict millions of people worldwide, yet they lack effective disease-modifying treatments. The main obstacle in treating neurodegenerative diseases such as Alzheimer’s has been penetrating the blood-brain barrier (BBB). In preliminary studies, Kurve’s patented Controlled Particle Dispersion® technology has been shown to bypass the blood-brain barrier and was able to deliver up to 30x more medication directly to the brain than infusions.

” An IV infusion manages to deliver one-tenth of one percent through the BBB. We have measured our success at 30 times more than that. This is not an insignificant achievement. Central nervous system disorders are a scourge because by their very nature, they are very difficult to treat. We have the potential to eliminate this problem so an unmet need becomes a met need,” commented Marc Giroux, Kurve Therapeutics CEO and founder.

About Kurve Therapeutics

Kurve Therapeutics ‘ drug delivery technology is designed to target the most difficult part of the treatment process — getting medication through the blood-brain barrier and into the brain.

Kurve Therapeutics has 18 peer-reviewed publications of clinical trials using their breakthrough technology, with further publications pending. The company has recent and ongoing collaborations with leading research centers including Harvard, Johns Hopkins, and the Karolinska Institute.

Through the development of their patented Controlled Particle Dispersion® technology, Kurve Therapeutics aims to reshape the landscape of cognitive aging, neurodegenerative diseases, and related disorders. Its next-generation technology has been shown to deliver up to 30x more disease-modifying medication directly to the brain than infusions in several Phase II studies. This allows for significant dose flexibility away from toxic doses for a safer, more efficacious therapy. While traditional treatment options continually prove ineffective at stopping neurodegenerative disease progression and often lead to toxicity or continued decline, Kurve is developing a new disease-modifying approach.